Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Phase 2

Recruiting

• Conditions: Endometrial Cancer
• Interventions: Radiation: Adjuvant radiotherapy (EBRT +/- brachytherapy); Radiation: Vaginal brachytherapy; Other: Observation

• Registration Number: NCT05640999
• Lead Sponsor: Canadian Cancer Trials Group

Brief Summary

This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies

* EN10.A/RAINBO BLUE: POLE-mutated EC

* EN10.B/TAPER: p53 wildtype / NSMP EC

Detailed Description

This study is being done in order to find out if this new approach is better or worse than the usual approach for early-stage endometrial cancer. The usual approach is defined as the care most people get for early-stage endometrial cancer.

The usual approach for patients who are not in a study is treatment with surgery. Tissue that is removed as part of this procedure is analyzed in the pathology laboratory to guide the doctor to decide whether or not additional treatment such as radiation and or chemotherapy should be recommended.

Study Timeline

• Study First Submitted: 2022-11-29
• Study First Submitted QC: 2022-11-29
• Study First Posted: 2022-12-07
• Study Start: 2022-12-19
• Status Verified: 2025-04
• Last Update Submitted: 2025-06-10
• Last Update Posted: 2025-06-11
• Primary Completion: 2028-12-31
• Study Completion: 2029-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 393

Inclusion Criteria

• Patients must have had surgery consisting of hysterectomy and bilateral salpingo-oophorectomy. Lymph node dissection can be performed as per institutional standards. There must be no macroscopic residual disease after surgery.
• Patients must have histologically confirmed Stage I to III endometrial carcinoma which can be endometrioid, serous, clear cell, un/dedifferentiated, carcinosarcoma or mixed.
• Patients' Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2.
• HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
• Patients' age must be ≥ 18 years.
• Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements.
• Patient is able (i.e. sufficiently fluent) and willing to complete the patient-reported outcomes (PRO) questionnaires in either English, French or a validated language
• Patients must be accessible for treatment and follow-up. Patients enrolled on this trial must be treated and followed at the participating centre
• Protocol treatment is to begin within 10 weeks of hysterectomy/bilateral salpingo-oophorectomy

Exclusion Criteria

• Prior Neoadjuvant chemotherapy for current endometrial cancer diagnosis.
• Prior pelvic radiation.
• Patients with a history of other malignancies, except: carcinoma in-situ without evidence of invasive disease when resected, adequately treated non-melanoma skin cancer, or other tumours curatively treated with no evidence of disease for ≥ 5 years.
• Clinical evidence of distant metastasis as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis or whole-body PET-CT scan)
• Patients with a documented positive surgical margin.
• Patients with a documented positive peritoneal washings, if performed.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sub-Study A: RAINBO BLUE Cohort A2 Exploratory	Adjuvant radiotherapy (EBRT +/- brachytherapy)	Observation or Adjuvant Radiotherapy
Sub-Study B: TAPER	Observation	Observation or Vaginal Brachytherapy
Sub-study A: RAINBO BLUE Cohort A1	Observation	Observation
Sub-Study A: RAINBO BLUE Cohort A2 Exploratory	Observation	Observation or Adjuvant Radiotherapy
Sub-Study B: TAPER	Vaginal brachytherapy	Observation or Vaginal Brachytherapy

Primary Outcome Measures

Name	Time	Method
Estimate the rate of pelvic recurrence at 3 years in patients who are treated with de-escalated adjuvant treatment directed by tumour molecular status	3 years

Secondary Outcome Measures

Name	Time	Method
Estimate recurrence-free survival	9 years
Estimate the rate of distant metastasis at 3 years	3 years
Estimate overall survival	9 years
Describe the impact of molecular classification on fear of recurrence by Fear of Recurrence Inventory	9 years
Estimate the rate of isolated vaginal recurrence at 3 years	3 years
Estimate the rate of para-aortic recurrence at 3 years	3 years
Estimate endometrial cancer-specific survival	9 years

Trial Locations

Locations (67)

Alaska Womens Cancer Care; 🇺🇸 Anchorage, Alaska, United States

University of Arizona Cancer Center; 🇺🇸 Tucson, Arizona, United States

Cedars-Sinai Medical Center; 🇺🇸 Los Angeles, California, United States

Huntington Memorial Hospital; 🇺🇸 Pasadena, California, United States

Sutter Medical Center Sacramento; 🇺🇸 Sacramento, California, United States

UCHealth University of Colorado Hospital; 🇺🇸 Aurora, Colorado, United States

Piedmont Hospital; 🇺🇸 Atlanta, Georgia, United States

Northwestern University; 🇺🇸 Chicago, Illinois, United States

Northwestern Medicine Cancer Center Warrenville; 🇺🇸 Warrenville, Illinois, United States

Ascension Saint Vincent Indianapolis Hospital; 🇺🇸 Indianapolis, Indiana, United States

Scroll for more (57 remaining)